We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Jose Miguel Lizcano De Vega, Head of group Protein kinases in cancer research (VHIR)
Summary: I will present the preclinical and clinical development of ABTL0812 (2-hydroxylinoleic acid), a first-in-class anticancer molecule. ABTL0812 selectively kills cancer cells by inducing endoplasmic reticulum (ER) stress and the UPR-mediated cytotoxic autophagy, without affecting healthy cells. Mechanistically, ABTL0812 inhibits desaturase-1, the last enzyme in the ceramide biosynthesis pathway, leading to an accumulation of long-chain dihydroceramides. This, in turn, results in the activation of ER stress and the unfolded protein response (UPR), ultimately inducing cytotoxic autophagy in cancer cells. This represents a novel therapeutic approach, highlighting the potential of ER stressors as effective anticancer agents. Clinical trial data demonstrate that ABTL0812 has a favourable safety and tolerability profile. Phase 2 clinical trials have shown that ABTL0812 enhances the efficacy of standard chemotherapy regimens in patients with advanced squamous non-small cell lung cancer (NSCLC) and advanced endometrial cancer. ABTL0812 is currently in Phase 2b clinical trial, as a first-line therapy in combination with FOLFIRINOX, for patients with advanced or metastatic pancreatic cancer. Additionally, I will present supporting preclinical data that provide a rationale for this clinical trial.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.